Michael J. LaBarre
2021
Compensation breakdown
| Non-Equity Incentive Plan | $270,217 |
|---|---|
| Option Awards | $450,010 |
| Salary | $494,000 |
| Stock Awards | $1,050,040 |
| Other | $15,333 |
| Total | $2,279,600 |
LaBarre received $1.1M in stock awards, accounting for 46% of the total pay in 2021.
LaBarre also received $270.2K in non-equity incentive plan, $450K in option awards, $494K in salary and $15.3K in other compensation.
Rankings
In 2021, Michael J. LaBarre's compensation ranked 5,523rd out of 12,405 executives tracked by ExecPay. In other words, LaBarre earned more than 55.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,523 out of 12,405 | 56th |
Division Manufacturing | 2,334 out of 5,494 | 58th |
Major group Chemicals And Allied Products | 1,012 out of 2,369 | 57th |
Industry group Drugs | 901 out of 2,090 | 57th |
Industry Biological Products, Except Diagnostic Substances | 221 out of 452 | 51st |
Pay ratio
| Michael J. LaBarre's Pay | $2,279,600 |
|---|---|
| Median Employee's Pay | $291,734 |
| Pay Ratio | 8to 1 |
In 2021, the annual total compensation of Michael J. LaBarre was $2,279,600.
The annual total compensation of the median employee at Halozyme Therapeutics was $291,734.
The ratio of Michael J. LaBarre's pay to the pay of median employee was therefore 8 to one.
LaBarre's colleagues
We found three more compensation records of executives who worked with Michael J. LaBarre at Halozyme Therapeutics in 2021.